Available in wide range of fluorochromes for research use only. Read More »

Laboratorios Salvat S.A.and Arbor Pharmaceuticals LLC recently partnered on the launch of OTOVEL (ciprofloxacin 0.3% and fluocinolone acetonide 0.025%) otic solution. Read More »

Vifor Pharma, which is owned by Galenica, will be combined with Relypsa to form an important cardio-renal care provider in the United States. Read More »

The decision by the FDA was done under accelerated approval with continued approval dependent on consequent trials verifying the clinical benefit of BLINCYTO. Read More »

If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. Read More »

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Catalyst Pharmaceuticals Inc. for Firdapse to treat myasthenia gravis (MG).e Read More »

Mylan NV yesterday announced that its inter-parties review (IPR) proceeding in regard to U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co. and licensed to Teva Pharmaceuticals, was ruled in its favor of by the U.S. Patent and Trademark Office (PTO) and found unpatentable. Read More »

The Journal of Community and Supportive Oncology recently published a study that presented two key research findings dealing with treatment options for breast cancer. Read More »

Taiho Ventures today announced that it has invested in Arcus Biosciences, a groundbreaking immuno-oncology company that develops small molecules and antibodies to combine with agents to form its own internal combinations. Read More »

Patent-protected Alzheimer's medication subject of infringement litigation. Read More »

Agreement gives Amgen global development and commercial rights to BI 836908 (AMG 420). Read More »

Voters concerned about health topics, especially affordability and accessibility and Medicare. Read More »

Adding Prolia to glucocorticoid therapy increases bone mineral density. Read More »

New life-saving diagnostic test recognized at the 2016 JOB/ACNBH Conference in Paris, France. Read More »

Portola Pharmaceuticals Inc. has announced that the Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress featured the interim results of its ongoing Phase 3b/4 ANNEXA-4 clinical trial of AndexXa (andexanet alfa). Read More »

Program designs synthetic oligonucleotide-based drug candidates for cancer and rare disease treatments. Read More »

CVS Health Corp. has announced that its President and CEO Larry Merlo will be giving a speech to investors at the Morgan Stanley Global Healthcare Conference on Sept. 13. Read More »

A ballot initiative supporters claim will lower drug prices in California is vague and poorly conceived, said a group with a long history of advocating for better cures and treatment for HIV and hepatitis C. Read More »

QIV flu vaccine protects against four common flu strains to maximize immunity during flu season. Read More »

NLS Pharma Group this week announced that it has begun enrollment for its Phase II clinical trial for Mazindol, which will be conducted on adults with DSM-5 Attention Deficit Hyperactivity Disorder (ADHD). Read More »